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INTRODUCTION
Since the successful development of methods for islet trans-
plantation (1) through the portal vein, the liver has become
the most widely used islet implantation site in clinical trials.
However, doubts have been raised about the liver as an ideal
islet transplantation site because of complications associated
with intraportal islet infusion, such as bleeding and throm-
bosis (2), low efficiency because of the primary loss of the
functional islet mass by an immediate blood-mediated inflam-
matory reaction (3), impossibility of graft retrieval (4), and
progressive deterioration of intrahepatic islet function (5) due
to the failure of engraftment.
Numerous sites have been investigated as an ideal islet im-
plantation site, including the kidney subcapsule (6, 7), liver
(6-8), peritoneum (8, 9) omental pouch (10), skeletal muscle
(9, 11), subcutaneous tissue (8, 11), and spleen (6). However,
it is difficult to determine the ideal implantation site based
on these published data because of the variety of donor islets
(fetal islet-like clusters vs. adult islets), the species of donor
and recipients (rat, mouse, and pig), the parameters used to
determine the success of implantation (metabolic control,
oxygen tension, or functional mass) and the number of sites
compared. In addition, no study has considered the operative
feasibility, which could affect the success rate of the transplan-
tation. A study comparing the numerous implantation sites
using the same strain as the donor and recipient and the same
parameters evaluated by a single operator to assess the suc-
cess rate would provide more practical information for deter-
mining the ideal islet implantation site.
To identify the optimal site for islet implantation, we assess-
ed operative feasibility, implantation efficiency, and glycemic
control efficiency and compared these between islets trans-
planted into four sites including the kidney subcapsule, liver,
muscle, and omental pouch, which are the most favourable sites
for engraftment. The pancreatic islets isolated from C57BL/6
mice were transplanted syngeneically into a group of inbred
streptozotocin-induced diabetic recipients at each of the four
sites. The operative time and mortality rate were measured
to assess operative feasibility. The implantation efficiency was
measured as the marginal mass that cured hyperglycemia,
and the mean time to reach euglycemia. The glycemic con-
trol efficiency was measured using an intraperitoneal glucose
tolerance test (IPGTT). 
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Comparison of Four Pancreatic Islet Implantation Sites
Although the liver is the most common site for pancreatic islet transplantation, it is
not optimal. We compared kidney, liver, muscle, and omentum as transplantation
sites with regard to operative feasibility, and the efficiency of implantation and glycemic
control. Islets from C57BL/6 mice were transplanted into diabetic syngeneic recipi-
ents. The mean operative time and mortality were measured to assess feasibility.
To assess implantation efficiency, the marginal mass required to cure diabetes and
the mean time taken to achieve normoglycemia were measured. A glucose toler-
ance test was performed to assess glycemic control efficiency. The data are listed
in the order of the kidney, liver, muscle, and omentum, respectively. The mean mor-
tality rate was 6.7, 20.0, 7.1, and 12.5%; the mean operative time was 10.2, 27.4,
11.2, and 19.8 min; the marginal islet mass was 100, 600, 600, and 200 islet equi-
valence units and the mean time to reach euglycemia was 3.0, 15.1, 26.6, and 13.9
days. The glucose kinetics of omental pouch islets was the most similar to controls.
Thus, a strategic approach is required for deciding on the best transplantation recip-
ient sites after considering donor sources and islet volume. Alternatives can be cho-
sen based on safety or efficacy.
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Mice
Male inbred C57BL/6 mice, aged 9 to 11 weeks, were used
as islet donors and recipients. All mice were obtained from
Korea Animal Technology (Koatech Inc., Seoul, Korea) and
maintained in the Seoul National University SPF animal facil-
ities. The experimental protocols were approved by the Insti-
tutional Animal Care and Use Committee. Diabetes was in-
duced by the intraperitoneal (IP) injection of streptozotocin
(Sigma-Aldrich, St. Louis, MO, USA). Streptozotocin (200
mg/kg) was dissolved in citrate buffer (Sigma) and used with-
in 5 min. Nonfasting blood glucose concentration was mea-
sured using a portable glucose analyzer (Beckman Instruments,
Fullerton, CA, USA) from samples obtained by tail snipping.
Mice with two consecutive nonfasting blood glucose concen-
tration measurements >350 mg/dL were used as recipients.
Islet isolation and preparation
Pancreatic islets were isolated from a healthy nondiabetic
mice. The common bile duct of the mouse was cannulated
and injected with 5 mL of Collagenase P solution (Roche,
Indianapolis, IN, USA) at 0.55 mg/mL in HEPES-buffered
Hanks’ balanced salt solution. The distended pancreas was
excised and digested for 20 min at 37℃. Islets were purified
with a discontinuous Ficoll gradient solution. The islets were
counted under a dissecting microscope. An algorithm was used
to calculate a 150-mm-diameter islet equivalent number (IEQ).
One donor yielded 100-200 IEQs. RPMI-1640 (Gibco Labo-
ratories, Grand Island Biological Co., Grand Island, NY, USA)
supplemented with 10% fetal bovine serum, glutamine, and
antibiotics (penicillin, streptomycin, and amphotericin B;
Gibco) was used as the culture medium. Before transplanta-
tion, the required number of islets for transplantation was
collected manually and prepared for transplantation.
Transplantation of islets to each site
Transplantation was performed about 5 days after the induc-
tion of diabetes. Ketamine (100 mg/kg, i.p.) and xylazine
(10 mg/kg, i.p.) were used for anaesthesia. The operative time
was defined as duration from the first incision to the final
skin closure. The operative mortality was defined as the death
of a mouse between the first incision until the first week after
transplantation. The transplantation methods were as follows.
In the kidney, an incision was made on the left flank, the kid-
ney was exposed, and islets were injected via a polyethylene
tube (PE-50, Becton Dickinson, Parsippany, NJ, USA) insert-
ed beneath the kidney capsule. In the liver, the bowel was
displaced to the left, the portal vein and superior mesenteric
vein were identified, and islets were injected into the portal
vein in a suspension form in 100 mL of phosphate-buffered
saline through a 30 G needle. After islet injection, the lumen
of the syringe was rinsed with about 50 mL of portal blood,
which was then reinjected to ensure complete injection of the
islets. The injected site was compressed for 5 min for hemosta-
sis, and the abdomen was closed carefully. The fluid remain-
ing in the injection syringe was collected and examined under
a microscope to identify any residual islets; this examination
revealed that <5% of the injected islets remained. For trans-
plantation into the muscle, the hind leg was immobilized,
incised to expose the calf muscle, and sharp dissection with
microscissors was used to make room for the islet transplan-
tation. Islets were injected via a polyethylene tube, and the
opening was ligated with a nonabsorbable suture. In the omen-
tum, an omental pouch was created with some modification
of a previous method (12). The greater omentum was iden-
tified and spread out before islet transplantation. The islet
pellet was placed on the omentum, which was then folded
upon itself, and the margin of the omentum was sutured with
a nonabsorbable suture.
Graft function analysis
The animals were observed for 3 months after surgery. The
nonfasting blood glucose concentration was monitored 3 times
a week using a portable glucose analyzer (Beckman Instru-
ments, Fullerton, CA, USA). The graft function was defined
as successful when the nonfasting blood glucose concentration
was <200 mg/dL and as failure when the nonfasting blood
glucose concentration was >200 mg/dL in two consecutive
samples. The marginal mass was defined as a subcurable dose
of IEQ that cured 50% of the engrafted diabetic mice. The
time to reach euglycemia was defined as the number of days
before blood glucose concentration lower than 200 mg/dL.
The IPGTT was performed each month after transplantation.
Briefly, after an overnight fast, 1.5 g/kg body weight of a
20% dextrose solution was injected, and the blood glucose
concentration was measured after 0, 2, 5, 10, 20, 40, 60, 90,
and 120 min.
Histological examination
Serial sections of the islet-bearing organs or tissues were
obtained to evaluate the morphology by staining with hema-
toxylin-eosin (H&E) and dithizone (Sigma) 45 or 90 days
after transplantation. Samples were embedded in OCT 4583
compound (Miles Inc., Elkhart, IN, USA), snap-frozen in liq-
uid nitrogen, and preserved at -70℃ in a deep freezer until
sectioned. The pancreas of a normal mouse was used as the
positive control for insulin staining. The islets implanted
into the omental pouch and kidney subcapsule were obtained
by omentectomy and nephrectomy, respectively, and the islets
transplanted into the liver were obtained by hepatectomy.
Graft-bearing calf muscle excision was used to obtain the islets
transplanted into the muscle. Staining with dithizone was
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cessed for H&E staining.
Statistical analysis
All results are expressed as the mean±standard error of
the mean (SEM) for the number of experiments indicated.
The data were analyzed using analysis of variance (ANOVA).
The Bonferroni correction was applied for multiple compar-
isons by dividing the Pvalue by the number of comparisons.
A Pvalue <5% was considered significant.
RESULTS
Operative feasibility
The operative feasibility was assessed as the operative time
and mortality rate (Table 1). Islet transplantation to the kid-
ney subcapsule and muscle required a very small incision,
which resulted in the short operation time of 10.2±0.4 min
and 11.2±0.4 min, respectively. Manipulation of these sites
caused few fatal problems and resulted in low mortality rates
of 6.7% and 7.1%, respectively. Transplantation into the liver
and omentum took 27.4±1.3 min and 19.8±0.9 min res-
pectively because of opening and closing of the peritoneum.
The operative mortality rate was 20.0% in the liver group
and 12.5% in the omentum group. The liver group had the
highest operative mortality and longest operative time, prob-
ably because the procedure involved direct access to the por-
tal vein, which might have caused bleeding that required
extra time for hemostasis. 
Implantation efficiency
Glycemic control was investigated after decreasing volumes
of islets were transplanted into each site. This sequential trans-
plantation was performed in the four transplantation sites.
The kidney group showed more consistent glycemic control
than the other groups (Fig. 1), and incidental hyperglycemic
event after transplantation occurred rarely. In the kidney group,
the mean time to reach euglycemia after transplantation was
3.0±1.0 days, which was the shortest of all groups (Table 1).
The kidney subcapsule was the most efficient site for islet trans-
plantation in terms of the marginal mass because it required
only 100 IEQs, the smallest value for all sites (Fig. 2). The
liver and muscle groups had a similar glycemic control pat-
tern, which showed poor glycemic control and took longer
time to function than in the other groups. The mean time
to reach euglycemia was 15.1±3.3 days in the liver group
and 26.6±5.9 days in the muscle group. The marginal mass
for both groups was 600 IEQs. Blood glucose concentration
was controlled strictly in the omental pouch group, and the
time to function (13.9±3.7 days) was shorter than in the liver
and muscle groups. The marginal mass was 200 IEQs in the
omental pouch group. A prompt return to hyperglycemia
after the removal of the islet graft in the kidney subcapsule,
muscle, and omental pouch groups demonstrated that the
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Results are expressed as the mean±SEM. Normal control mouse was used for comparison of mean glucose level and IPGTT AUC.
*Mean glucose concentration was checked only for the cured mouse.
a,c,lP<0.05, 
b,d,m,nP<0.01, groups with the same letter differ significantly from each other, ANOVA for the comparison between five groups; 
e,f,oP<0.05, 
g,h,kP<
0.01, groups with the same letter differ significantly from each other, ANOVA for the comparison between four groups; 
ipercentage of mice that died
from the time of the first incision until one week after transplantation; 
jthe number of islets when half of the mice transplanted with those amounts of islets
could be successfully cured from hyperglycemia.
AUC, area under the curve; IPGTT, intraperitoneal glucose tolerance test.
Group
Control (n=8)
Parameters
Kidney (n=15) Liver (n=38) Muscle (n=28) Omentum (n=16)
Transplantation result
Success (n) 8 8 8 8
Failure (n) 6 16 18 6
Operative mortality (n) 1 6 2 2
Mean glucose concentration* (mg/dL) 174.6±4.4
a,b,c 138.8±5.9
a 135.1±6.3
b,d 158.3±5.8
d 152.4±2.8
c
Operative feasibility
Operative time (min) 10.2±0.4
e,f 27.4±1.3
g,f 11.2±0.4
g,h 19.8±0.9
e,h
Operative mortality
i (%) 6.7 20.0 7.1 12.5
Implantation efficiency
Marginal mass
j (islets) 100 600 600 200
Time to reach euglycemia (days) 3.0±1.0
k 15.1±3.3 26.6±5.9
k 13.9±3.7
Glycemic control efficiency
IPGTT AUC (min×mg/dL) 29,868±3,492
l,m,n 42,607±2,535
l 46,528±1,673
m 47,376±10,184
n,o 35,082±6,915
o
Table 1. Summary of the transplantation success rate, operative feasibility, implantation efficiency, and glycemic control efficiency of
each transplantation site compared with the normal controlblood glucose concentration was controlled by the islet grafts
and not by the residual endogenous islet. We could not remove
the islet graft from the liver group because a hepatectomy is
not a survival surgery. The correlation between the mean time
to reach euglycemia and transplanted isle volume was assessed
but was not statistically significant.
Glycemic control efficiency
The glucose tolerance test was performed only in the mice
that had been cured of hyperglycemia by successful islet trans-
plantation. Fig. 3 shows the blood glucose concentration after
glucose challenge in each group. The area under the curve
(AUC) was calculated and the differences in glucose clear-
ance kinetics between groups were analyzed by ANOVA. The
omental pouch group showed the most effective glucose clear-
ance, which did not differ significantly from that in the nor-
mal control animal. Other sites showed poor glucose clear-
ance kinetics. Muscle showed the most delayed and lowest
glucose clearance rate.
Histological findings
Fig. 4 shows the histological findings of the engrafted islets
in each transplantation site stained with dithizone and H&E
3 months after transplantation. The dithizone staining on
unfixed cryosectioned tissue revealed insulin-containing islets
promptly. Further staining with H&E showed intact and
well-preserved islets without surrounding steatosis in the
tissue of each transplantation site. 
DISCUSSION
Our study demonstrates the characteristics of each islet im-
plantation site, including the kidney subcapsule, liver, omen-
tal pouch, and muscle, and that each has advantages in terms
of the operative feasibility, implantation efficiency, and gly-
cemic control efficiency. Although many studies have inves-
tigated the ideal islet implantation site using various char-
acteristics, none has compared the four sites within the same
recipient-donor pair and according to the same parameters.
In this respect, our study provides unique data. Using one
operator and comparing the four sites, one study allowed us
to exclude variables that could influence the experimental
results. One advantage of our study is our measurement of
implantation efficiency, which allowed us to determine the
actual marginal mass or the subcurable dose that can cure
diabetes in 50% of recipients for each site. The transplanted
islet mass was scaled down by 100 IEQs from the large vol-
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Fig. 1. The change in blood glucose concen-
tration for individual mice in the four transplan-
tation groups. Only the blood glucose concen-
tration of successfully treated mice is plotted.
The arrows indicate the excision of islet-bear-
ing grafts and show a prompt increase in blood
glucose concentration except for the liver trans-
plantation group. The kidney transplantation
group has the shortest time to reach euglyce-
mia after transplantation and lower glucose
baseline with strict metabolic control. The mus-
cle transplantation group shows delayed func-
tion after transplantation and a higher base-
line with frequent events of glucose concen-
trations >200 mg/dL.
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Days post transplantationume of islets enough to cure diabetes; for example, the mass
was 1,500 IEQs in the muscle group and 300 IEQs in the
kidney group. The largest islet mass that could no longer
control hyperglycemia was defined as the tentative marginal
mass. Finally, the marginal mass was identified by increasing
the number of transplantation cases with the amount of islets
around the tentative marginal mass. This sequential dose-
decreasing method differs from that used in previous stud-
ies, in which the same amount of islets was transplanted into
different sites, and the implantation efficiency was measured
only by comparing the success rate (6-8, 11).
An ideal graft recipient site (10, 13, 14) should provide an
easy access for transplantation and retrieval, a safe procedure,
a trophic effect for maximal islet graft and survival, effective
hormone secretion within the physiologic location and im-
munologic privilege for inducing a donor-specific unrespon-
siveness in the allograft. It should also reduce molecular in-
compatibility associated with islet destruction between the
donor and recipient when used in the xenograft. The param-
eters used in our study could provide the right information
to evaluate all these factors except for the latter two. How-
ever, determining the operative feasibility, implantation effi-
ciency, and glycemic control efficiency in a syngeneic mouse
model could provide suitable background data to determine
an optimal site in allogeneic and xenogeneic models.
The kidney and liver are the most extensively studied organs
as candidates for islet implantation sites. In our study, the kid-
ney gave the best results, with the shortest operative time,
lowest operative mortality, smallest marginal mass, shortest
time to reach euglycemia, and strictest glucose control. How-
ever, the human kidney subcapsule is inelastic and has lim-
ited space beneath it that cannot accommodate large amounts
of islets, and the implanted islets can deteriorate easily because
of exocrine contamination (15). These critical limitations res-
trict the clinical application of islet transplantation into the
kidney subcapsule. One report on human allograft transplan-
tation into a kidney site had poor results (16).
Successful human allo-islet transplantation (1) has made
the liver the standard organ of choice for islet transplantation.
The intraportal islet transplantation procedure is very sim-
ple. Achieving a high drug concentration in the portal vein
may increase the chance of tolerance induction with a lower
total drug administration volume (17). However, the portal
vein infusion procedure causes immediate destruction of large
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Fig. 2. Marginal mass of islets for each transplantation site. Each
point represents the transplanted islet volume and average blood
glucose concentration. The filled circles indicate successful islet
transplantation associated with normoglycemia. The empty circles
indicate failed islet transplantation associated with hyperglycemia.
The marginal masses for the kidney, liver, muscle, and omentum
are 100, 600, 600, and 200 islets, respectively. Note that the liver
and muscle transplantation groups show a wider range of glucose
control ability in relation to the marginal mass, whereas the kidney
and omentum transplantation groups show a sharp decline in glu-
cose control ability in relation to the marginal mass.
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Fig. 3. Glucose tolerance test results of the four groups compar-
ed with the normal control. The intraperitoneal glucose tolerance
test was performed 3 months after transplantation. The solid line
indicates the blood glucose response in the normal control. The
blood glucose concentration decreases faster in the omentum
transplantation group (    ) than in the others. The area under the
curve does not differ significantly between the omentum transplan-
tation group and normal controls. Individual curves have been
shifted slightly to prevent overlap. The values are expressed as
the mean±SEM. The area under the curve was calculated and
analyzed using ANOVA. 
*P<0.05 vs. control group; 
� P<0.01 vs. the control group; 
� P<0.05
between omentum and muscle groups (    ) kidney, (    ) liver and,
(    ) muscle. 
IPGTT, intraperitoneal glucose tolerance test.
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�amounts of islets (3), and this phenomenon would be more
evident in the xenograft setting because of the molecular in-
compatibility between species (18). The portal transplanta-
tion of islets can induce hepatocellular carcinoma (19). In
terms of the physiology, one study reported on the placement
of embolized islets within hepatic cords along the distal sinu-
soid (20). Most of the secreted insulin is released directly into
the systemic circulation, so most hepatocytes are not exposed
to high insulin concentrations (21), leaving focal, microscopic
regions of liver that receive insulin. This may explain why the
liver group showed no physiological advantage in the IPGTT
study. The large volume of marginal mass and high mortal-
ity rate in our study do not support the idea of the liver as an
ideal islet transplantation site. It was surprising that implan-
tation to the liver via the portal vein showed shorter function
recovery time than expected. For unknown reasons, there have
been very few reports on syngeneic mouse islet transplanta-
tion into the liver. We speculate that the high mortality rate
and delayed recovery of function might have contributed to
this. One report with details of individual glucose levels (22)
showed a shorter recovery time than we found here, but some-
what delayed implantation.
Muscle is thought to provide easier surgical access (9). This
is consistent with our operative feasibility assessment show-
ing a low mortality rate and short operative time. The muscle
could provide a safer route for xeno-islet implantation than
the portal vein by decreasing the effect of immediate islet
destruction, which may be stronger in the xenogeneic set-
ting because of the molecular incompatibility. However, the
lower angiogenic potential or vascularity would be a major
drawback. This site took more time to function and required
a large amount of islets compared with the other sites inves-
tigated. Despite these limitations, further study should focus
on improving the engraftment by enhancing angiogenesis
because the muscle site provides a significant logistical advan-
tage and minimally invasive route.
The omentum has a major disadvantage in that repeated
transplantation is not allowed. For the same reason, it can-
not be an islet transplantation site in a patient who requires
laparotomy for any reason. Furthermore, access and manip-
ulation of the omentum may offer minimal risks of intesti-
nal adhesion and obstruction. However, the omentum offers
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Fig. 4. Dithizone and H&E staining of the four transplantation sites and the histological appearance of an islet graft at 3 months after trans-
plantation. Note the pinkish stained areas of the engrafted islets. Dithizone staining of the section provided instant localization of the islets
in the kidney (A), liver (B), muscle (C), and omentum (D). Dithizone staining, original magnification ×50. H&E staining, original magnifi-
cations ×50 and ×100.
A B
C Dsome advantages. First, its blood supply and drainage resem-
bles the original islet-blood relationship (12). In our study,
islets in the omental pouch produced a glycemic AUC that
was most similar to control animals in terms of the IPGTT,
reflecting a physiologically normal delivery of insulin. It can
be argued that intraperitoneal glucose injections could be an
advantage in directly stimulating omentally engrafted islets
and could give better glycemic control. Considering the very
limited surface area of the manipulated omental pouch attach-
ed to the stomach wall, the chance for the islet to contact glu-
cose directly during an IPGTT performed at least one month
after transplantation would be negligible. Intravenous glu-
cose tolerance testing might confirm this point. Second, it
can accommodate a large islet volume (12). This character-
istic feature may provide enough space for encapsulated islets
or cotransplanted material. Third, the omentum offers bet-
ter survival (23) of unpurified islets than do other sites. Con-
sidering the low purity of isolated human islets, this site may
offer a great advantage for allogeneic islet transplantation.
To assess the glycemic control efficiency, we performed an
IPGTT each month after transplantation during the obser-
vation period and found that the glucose clearance did not
change over time. For this reason, for those mice undergoing
graft resection before 3 months, the AUC obtained from the
first month’s IPGTT was used for comparison. Even though
we compared the successful groups, these were heterogeneous
in terms of islet volume. However, there was no significant
difference between the four lowest and four highest volumes
of islets among the eight successful recipient mice for each
site (data not shown). It is known that once above the thresh-
old, further increase in islet mass is not associated with any
increase in glucose clearance (24).
Eventhough we tried to evaluate four implantation sites
for pure islets engraftment capacity comparisons for clinical
application, it has some limitations. First, this syngeneic mouse
model does not allow assessment of immunologic rejection
or molecular incompatibility between the donor and recipi-
ent. Therefore, the same results would not be expected in allo-
geneic or xenogeneic islet transplantation models. Second,
the results of small animal experiments might not be appli-
cable directly to large animals or humans. Third, islet trans-
plantation via portal vein is usually performed percutaneous-
ly by radiologic intervention in clinical setting. This differs
from this study method in which laparotomy was inevitable.
In this regard, the operative time and mortality of liver trans-
plantation group might have been overestimated. Fourth, six
fold higher numbers of islets to cure mice after intraportal
transplantation and fifteen days for normalization of blood
glucose requires further optimization of transplantation tech-
nique.
However, our results imply that the omental pouch could
be the optimal site in terms of implantation and glycemic
control efficiency, although the results in IPGTT would be
overestimated due to the direct contact between the challeng-
ed glucose and the implanted islets. On the other hand, mus-
cle could be an attractive site of choice in terms of operative
feasibility. If only an engraftment enhancing method is devel-
oped, muscle could be an excellent alternative site.
In summary, we evaluated and compared islet transplanta-
tion into four sites in terms of the marginal mass, operative
feasibility, and glycemic control efficiency. A strategic approach
is required for deciding on the best transplantation recipient
sites after considering the available donor source and volume
of islets. Alternatives can be chosen based on safety or efficacy.
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